Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Endocrine 7NET 4Breast 3Plasma cell 2Genitourinary 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Primary Inoperable Thymoma 1

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × pasireotide × Thoracic × Clear all
NCT02021942 2018-02-05

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

University of Regensburg

Phase 2 Completed
16 enrolled 11 charts
Thoracic

Primary Inoperable Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡